A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

BACKGROUND: Crizotinib inhibits ALK, MET and ROS1 tyrosine kinases but the development of resistance to monotherapy is an issue. The anti-angiogenic properties of pazopanib could overcome crizotinib drug resistance. Additionally, the anti-angiogenic properties of crizotinib could augment the clinica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Piha-Paul, Sarina A, Dumbrava, Ecaterina E, Nair, Binoj C, Xiong, Wendy, Xu, Li, Mostorino, Rosa, Subbiah, Vivek, Tannir, Nizar, Fu, Siqing, Naing, Aung, Janku, Filip, Karp, Daniel D, Patel, Shreyaskumar, Daw, Najat C, Hong, David, Meric-Bernstam, Funda, Zinner, Ralph
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2021
Assuntos:
Clinical Trial Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8114359/
https://ncbi.nlm.nih.gov/pubmed/33994796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S291801
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados